We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bionik Laboratories Corporation (CE) | USOTC:BNKL | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
UNITED STATES
|
SECURITIES AND EXCHANGE COMMISSION
|
WASHINGTON, DC 20549
|
|
FORM 8-K/A
|
(Amendment No. 1)
|
CURRENT REPORT PURSUANT
|
TO SECTION 13 OR 15(D) OF THE
|
SECURITIES EXCHANGE ACT OF 1934
|
|
Date of
report (Date of earliest event reported):
May 19, 2017
|
BIONIK
LABORATORIES CORP.
|
(Exact
Name of Registrant as Specified in Its Charter)
|
Delaware
|
|
000-54717
|
|
27-1340346
|
(State
or Other Jurisdiction of Incorporation or
Organization)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
483 Bay Street, N105
Toronto, ON
|
|
M5G 2C9
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code:
(416) 640-7887
|
||
|
||
(Former
Name or Former Address, if Changed Since Last Report)
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
|
Emerging
growth company ☐
|
|
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 1.01
|
Entry Into a Material Definitive Agreement
|
Item 2.03
|
Creation of a Direct Financial Obligation or an Obligation under an
Off-Balance Sheet Arrangement of a Registrant
|
Item 5.02
|
Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers
|
|
BIONIK LABORATORIES CORP.
|
|
|
|
|
|
By:
|
/s/
Peter
Bloch
|
|
Name:
|
Peter
Bloch
|
|
Title:
|
Chairman
and Chief Executive Officer
|
1 Year Bionik Laboratories (CE) Chart |
1 Month Bionik Laboratories (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions